We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Citations to Delay Indian Drugmaker Lupin’s U.S. Expansion
FDA Citations to Delay Indian Drugmaker Lupin’s U.S. Expansion
Indian drugmaker Lupin is facing delays in expanding its presence in the U.S. market after an FDA inspection uncovered deficiencies at a company facility.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor